Actualités de Zealand Pharma

Dernières actualités

Titres dans la langue d'origine de la source.

• 
  Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 5 oct. 2026

• 
  Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts (s'ouvre dans un nouvel onglet)

  1 oct. 2026

• Zealand Pharma Reports 13.1% Weight Loss in Phase 3 Survodutide Trial (s'ouvre dans un nouvel onglet)

  MT Newswires · 1 oct. 2026

• 
  Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 1 oct. 2026

• 
  Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 30 sept. 2026

• 
  Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 29 sept. 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 28 sept. 2026

• 
  Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 22 sept. 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 21 sept. 2026

• 
  Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 18 sept. 2026

• 
  Zealand Pharma (CPSE:ZEAL) Grants Exclusive Type 1 Diabetes Peptide License (s'ouvre dans un nouvel onglet)

  Simply Wall St. · 18 sept. 2026

• Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes (s'ouvre dans un nouvel onglet)

  15 sept. 2026

• 
  Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 14 sept. 2026

• 
  Zealand Pharma increases its share capital as a result of the exercise of employee warrants (s'ouvre dans un nouvel onglet)

  GlobeNewswire · 10 sept. 2026

• Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference (s'ouvre dans un nouvel onglet)

  9 sept. 2026

• Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) (s'ouvre dans un nouvel onglet)

  7 sept. 2026

• Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (s'ouvre dans un nouvel onglet)

  2 sept. 2026

• Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough (s'ouvre dans un nouvel onglet)

  1 sept. 2026

• Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) (s'ouvre dans un nouvel onglet)

  31 août 2026

• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (s'ouvre dans un nouvel onglet)

  28 août 2026